BCM
BBIO icon

Boone Capital Management’s BridgeBio Pharma BBIO Stock Holding History

Boone Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17M Buy
228,829
+43,866
+24% +$3.18M 5.21% 10
2025
Q4 		$14.1M Sell
184,963
-275,319
-60% -$18.1M 4.44% 12
2025
Q3 		$23.9M Buy
+460,282
New +$22.4M 7.84% 5
2024
Q1 		– Sell
-440,845
Closed -$17.8M – 23
2023
Q4 		$17.8M Buy
440,845
+127,464
+41% +$3.83M 4.15% 13
2023
Q3 		$8.26M Buy
+313,381
New +$8.89M 2.61% 13

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Boone Capital Management's BBIO Position: Q1 2026 in Review

Boone Capital Management increased its BridgeBio Pharma (BBIO) stake by 24% in Q1 2026, buying an estimated $3.18M and bringing the position to 228,829 shares worth $17M. The position accounts for 5.21% of the portfolio, ranked #10.

Boone Capital Management first reported a position in BBIO in Q3 2023 and has held it in 5 quarters since. The position peaked at $23.9M in Q3 2025. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Boone Capital Management held 228,829 shares of BridgeBio Pharma worth $17M as of Q1 2026.
  • Boone Capital Management bought 43,866 BridgeBio Pharma shares in Q1 2026, an estimated $3.18M.
  • BridgeBio Pharma made up 5.21% of Boone Capital Management's portfolio in Q1 2026, its #10 holding.
  • Boone Capital Management first reported a position in BridgeBio Pharma in Q3 2023 and has held it in 5 quarters since.
  • Boone Capital Management's BridgeBio Pharma position peaked at $23.9M in Q3 2025.
  • 457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Boone Capital Management's 13F filing for Q1 2026, filed 15 May 2026.